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Sialylation of lacto-N-neotetraose (LNnT) extending from heptose I (HepI) of 23 
gonococcal lipooligosaccharide (LOS) contributes to pathogenesis. Previously, 24 
gonococcal LOS sialyltransterase (Lst) was shown to sialylate LOS in Triton X-100 25 
extracts of strain 15253, which expresses lactose from both HepI and HepII, the minimal 26 
structure required for mAb 2C7 binding. Ongoing work has shown that growth of 15253 27 
in cytidine monophospho-N-acetylneuraminic acid (CMP-Neu5Ac)-containing media 28 
enables binding to CD33/Siglec-3, a cell surface receptor that binds sialic acid, 29 
suggesting that lactose termini on LOS of intact gonococci can be sialylated. Neu5Ac 30 
was detected on LOSs of strains 15253 and a MS11 mutant with only lactose from HepI 31 
and HepII by mass spectrometry; deleting HepII lactose rendered Neu5Ac undetectable. 32 
Resistance of HepII lactose Neu5Ac to desialylation by α2-3-specific neuraminidase 33 
suggested an α2-6-linkage. Although not associated with increased factor H binding, 34 
HepII lactose sialylation inhibited complement C3 deposition on gonococci. 15253 35 
mutants that lacked Lst or HepII lactose were significantly attenuated in mice, 36 
confirming the importance of HepII Neu5Ac in virulence. All 75 minimally passaged 37 
clinical isolates from Nanjing, China, expressed HepII lactose, evidenced by reactivity 38 
with mAb 2C7; mAb 2C7 was bactericidal against the first  62 (of 75) isolates that had 39 
been collected sequentially and were sialylated before testing. mAb 2C7 effectively 40 
attenuated 15253 vaginal colonization in mice. In conclusion, this novel sialylation site 41 
could explain the ubiquity of gonococcal HepII lactose in vivo. Our findings reiterate the 42 
candidacy of the 2C7 epitope as a vaccine antigen and mAb 2C7 as an 43 
immunotherapeutic antibody.  44 
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Introduction  45 
 Gonorrhea affects about 78 million people annually worldwide (1); almost 46 
470,000 of these are reported in the U.S. Multidrug-resistant gonorrhea has been 47 
reported on every continent and is a serious public health concern (2-6). Understanding 48 
how gonococci evade host immune defenses is an important step toward development 49 
of urgently needed safe and effective vaccines and novel therapeutics against this 50 
infection.  51 
N. gonorrhoeae is a uniquely human-adapted pathogen (7). On a molar basis, 52 
lipooligosaccharide (LOS) is the most abundant gonococcal outer membrane molecule 53 
and plays a key role in many facets of pathogenesis (8-19).  Host-like glycans 54 
expressed by lipooligosaccharide (LOS) of N. gonorrhoeae constitutes an example of 55 
molecular mimicry (8, 20).Two structures expressed by Neisserial LOS from heptose 56 
(Hep) I that mimic host glycans include lacto-N-neotetraose (LNnT; Galβ1-4GlcNAcβ1-57 
3Galβ1-4Glcβ1-), identical to the terminal tetrasaccharide of paragloboside, a precursor 58 
of the major human blood group antigens (21), and globotriose (Galα1-4Galβ1-4Glcβ1-) 59 
that is identical to terminal globotriose trisaccharide of the PK-like blood group antigen 60 
(22). The seminal work of Harry Smith and colleagues showed that N. gonorrhoeae 61 
scavenge cytidine monophospho-N-acetylneuraminic acid (CMP-Neu5Ac) from its host 62 
to sialylate its LOS (23, 24). Both, LNnT and PK-like LOSs can be sialylated (25, 26). 63 
LOS sialylation inhibits complement activation and converts strains that are otherwise 64 
sensitive to killing by complement in serum to a ‘serum (or complement)-resistant’ 65 
phenotype (16, 27-29). Several other microbes also use sialic acid expression to their 66 
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advantage to subvert host immunity (30-41), by mimicking host sialic acid-based “self- 67 
associated molecular patterns" 68 
Among members of the species Neisseria, the gonococcus uniquely expresses 69 
lactose extending from HepII. A monoclonal antibody (mAb) called 2C7 binds an 70 
epitope on LOS that requires expression of HepI and HepII lactose. Despite being under 71 
control of a phase variable LOS glycosyltransferase (lgt) gene called lgtG, HepII lactose 72 
is expressed by ~95% of clinical isolates of N. gonorrhoeae (42), which suggests a key 73 
role in virulence. Isogenic mutant strains that lack lgtG show decreased virulence in the 74 
mouse vaginal colonization model of gonorrhea (43). Why HepII lactose promotes 75 
gonococcal virulence remains unclear. In recent work, we noted that growth of a 76 
gonococcal strain called 15253 that expresses lactose simultaneously from HepI and 77 
HepII (44) was capable of binding to Siglec-3 when grown in CMP-Neu5Ac-containing 78 
media (45). Siglec-3 binds exclusively to sialyoglycans (46, 47). These data suggested 79 
that lactose expressed by N. gonorrhoeae LOS could also be sialylated. This study 80 
describes sialylation of gonococcal LOS lactose termini and elucidates its function in 81 
complement evasion and virulence.  82 
 83 
  84 
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Results  85 
Neu5Ac ‘caps’ N. gonorrhoeae HepII lactose. LOS glycan extensions from 86 
HepI and HepII for the strains used in this study are shown in Fig. 1. The ability of 87 
strains 15253 and MS11 2-Hex/G+, which express lactose extending from HepI and 88 
HepII, and their respective isogenic mutants, 15253/G- and MS11 2-Hex/G-, which 89 
express only lactose only from HepI, to add Neu5Ac to LOS was determined by SDS-90 
PAGE. MS11 4-Hex/G- (expresses LNnT LOS from HepI) was used as a positive 91 
control for sialylation. An lst deletion mutant of 15253 (15253 Δlst) that lacks the ability 92 
to sialylate its LOS was also tested to address whether the previously described Lst 93 
enzyme is also responsible for sialylation of lactose. 94 
Bacteria were grown in media alone, or media supplemented with 100 µg/ml 95 
CMP-Neu5Ac for maximal LOS sialylation. As shown in Fig. 2, the upper band in the ‘+’ 96 
lane of 2-Hex/G+ shows slower mobility compared to the upper band in the 97 
corresponding ‘-’ lane. Note that despite fixing lgtG ‘on’, MS11 2-Hex/G+ expresses an 98 
LOS species with only HepI lactose (i.e., the LOS expressed by MS11 2-Hex/G-). This 99 
is because of export of LOS to the outer membrane prior to addition of the proximal Glc 100 
on HepII, as noted previously (48). Similarly, retarded mobility of 15253 LOS was also 101 
observed when grown in media containing CMP-Neu5Ac. The LOS of 4-Hex/G- 102 
(positive control for sialylation) incorporated Neu5Ac and migrated slower. There was 103 
no appreciable alteration in LOS migration when 2-Hex/G-, 15253/G- or 15253 Δlst 104 
were grown in CMP-Neu5Ac, suggesting that Neu5Ac was added to the terminal Gal of 105 
HepII lactose and that Lst was the enzyme responsible for sialylation.   106 
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Mass spectroscopic analysis of LOS purified from strains 15253, 15253/G-, 107 
MS11 2-Hex/G+ and MS11 2-Hex/G- grown in CMP-Neu5Ac and unsialylated 15253 108 
(negative control) is shown in Supplemental Table S1. The data confirm the presence of 109 
sialic acid on 15253 and MS11 2-Hex/G+, but not on their isogenic mutants lacking 110 
HepII lactose. Collectively, the data strongly suggest that Neu5Ac is added to HepII 111 
lactose.     112 
 113 
Sialylation of HepII lactose does not enhance FH binding. Previously, we 114 
showed that sialylation of N. gonorrhoeae LNnT LOS, but not PK-like LOS, enhances 115 
human FH binding (26). We used strain MS11 to determine whether sialylation of HepII 116 
lactose enhances FH binding because this strain expresses PorB.1B and binds FH 117 
relatively weakly in the unsialylated state (49), which would more readily reveal 118 
increased FH binding with sialylation, if it were to occur. By contrast, strain 15253 119 
(PorB.1A) binds high levels of FH even when unsialylated (49), which would limit the 120 
ability to detect an increase in FH binding with sialylation. FH binding to MS11 LOS 121 
mutants that expressed 2, 3 or 4 hexoses from HepI, each with (G+) or without (G-) 122 
HepII lactose was examined. The 3-Hex (PK-like LOS) and 4-Hex (LNnT) mutants 123 
served as negative and positive controls for FH binding with sialylation, respectively. As 124 
shown in Fig. 3, growth of the 2-Hex mutants in CMP-Neu5Ac did not enhance FH 125 
binding. Thus, enhanced FH binding to N. gonorrhoeae is restricted to LNnT LOS.  126 
 127 
HepII lactose sialylation regulate complement activation. Neu5Ac capping of 128 
gonococcal LNnT and PK-like LOS both inhibit complement. N. gonorrhoeae bind C4BP 129 
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and FH in a human-specific manner (50, 51). Initial attempts at measuring human C3 130 
fragment deposition by flow cytometry on the two unsialylated strains using normal 131 
human serum revealed levels too low to discern the effects of sialylation on C3 132 
deposition. Therefore, we used mouse complement, whose C4BP and FH do not bind 133 
N. gonorrhoeae, to study the effects of LOS sialylation on C3 deposition. Consistent 134 
with the addition of Neu5Ac to HepII lactose, C3 deposition decreased only on wild-type 135 
15253 grown in media containing CMP-Neu5Ac (Fig. 4). Neither 15253/G- nor 15253 136 
Δlst inhibited C3 deposition when grown in CMP-Neu5Ac, consistent with the inability of 137 
these two mutant strains to sialylate their LOSs.  138 
We next examined the effects of sialylation on complement activation on six 139 
MS11 LOS mutants (Fig. 5). The sialylatable 3-Hex and 4-Hex strains served as 140 
controls for Neu5Ac-mediated complement inhibition. Growth in media containing CMP-141 
Neu5Ac decreased C3 deposition all tested strains. Similar to 15253, sialylation of 142 
MS11 2-Hex/G+ also inhibited C3 deposition. In contrast to 15253/G-, we noted a 143 
reproducible decrease in C3 deposition on the 2-Hex/G- mutant, suggesting that 144 
Neu5Ac was also added to the LOS of this strain. The degree of inhibition seen with 145 
sialylation of MS11 2-Hex/G- (a 4.1-fold decrease compared to the unsialylated parent, 146 
and 7.3-fold above baseline conjugate control levels) was less than that seen with 147 
complement inhibition upon sialylation of MS11 2-Hex/G+ (a 21-fold decrease 148 
compared to unsialylated 2-Hex/G+, and only 3-fold greater fluorescence compared to 149 
the baseline conjugate control). This amount of LOS sialylation of MS11 2-Hex/G- LOS, 150 
although functional, was too small to be appreciated by changes in mobility on a Tricine 151 
gel or by MS analysis.  152 
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To discern the sialic acid linkage to HepII substituted lactose we examined the 153 
effect of α2-3-linkage-specific neuraminidase on mouse C3 deposition (Fig. 6).  154 
Sialylated 2-Hex/G+ and the corresponding wild-type strain 15253 that possessed the 155 
same pattern of Hep I and Hep II hexose substitutions, failed to show increased C3 156 
deposition after treatment with recombinant α2-3-specific sialidase followed by 157 
incubation with 15% normal mouse serum; resistance to α2-3-sialidase suggests an α2-158 
6 linkage. 159 
   160 
Loss of sialic acid on HepII lactose impairs N. gonorrhoeae vaginal 161 
colonization in mice. The ability of 15253 (wild-type), 15253/G- and 15253 Δlst to 162 
colonize the genital tract of Cmah knockout (KO) mice was compared. Cmah KO mice 163 
lack the enzyme CMP-N-acetylneuraminic acid hydroxylase (CMAH) and akin to 164 
humans, cannot convert Neu5Ac to Neu5Gc. Thus, these mice provide a ‘human-like’ 165 
sialic acid milieu to study the effects of LOS sialylation on virulence. Cmah KO mice 166 
support N. gonorrhoeae colonization slightly better than control wild-type BALB/c mice 167 
(52). Loss of either HepII lactose or Lst significantly attenuated the duration and burden 168 
of bacterial colonization (Fig. 7A-C). These data provide strong evidence for the 169 
importance of sialylation of HepII lactose in gonococcal virulence. We were unable to 170 
evaluate the effects of LOS sialylation in MS11 2-Hex/G+ because this strain colonized 171 
mice for only 3 days (data not shown).  172 
 173 
Effect of sialylation on mAb 2C7 binding and efficacy. mAb 2C7 targets a 174 
LOS epitope being developed as a gonococcal vaccine candidate. The minimal LOS 175 
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structure required for mAb 2C7 binding are lactoses simultaneously extending from both 176 
HepI and HepII. Glycan extensions beyond lactose on HepII, for example with GalNAc-177 
Gal seen in a mutant strain selected under pyocin pressure called JW31R, abrogates 178 
mAb 2C7 binding (53). We therefore asked whether sialylation of HepII lactose affected 179 
mAb 2C7 binding and function. While sialylation of 15253 did not affect mAb 2C7 180 
binding (Fig. 8A, left graph), sialylation of MS11 2-Hex/G+ resulted in a reproducible ~2- 181 
to 3-fold reduction in mAb 2C7 binding (Fig. 8A, right graph). Similar binding of mAb 182 
2C7 to sialylated and unsialylated 15253 allowed us to assess the functional effects of 183 
HepII lactose sialylation when antibody binding was kept constant. As shown in Fig. 8B, 184 
increasing amounts of CMP-Neu5Ac in media caused a dose-dependent decrease in 185 
killing by mAb 2C7.  186 
 187 
mAb 2C7 is active against strain 15253 in vivo. In light of prior work that 188 
showed the importance of LOS sialylation for infection of mice (54, 55) and the 189 
observed resistance of sialylated 15253 to mAb 2C7 in vitro (Fig. 8), we examined the 190 
efficacy of mAb 2C7 versus 15253 in the BALB/c mouse vaginal colonization model. A 191 
‘passive immunization model’ to address the efficacy of mAb 2C7 to simulate effects of 192 
vaccine antibody was used (43). Wild-type BALB/c mice (n=8) were administered mAb 193 
2C7 10 µg intraperitoneally on Days -2, -1 and 0, and CFUs were monitored daily. The 194 
control group (n=7) received mouse IgG3. mAb 2C7 significantly shortened the duration 195 
and burden of infection with 15253 (Fig. 9A-C).   196 
 197 
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Expression of the 2C7 epitope by contemporary clinical isolates of N. 198 
gonorrhoeae. Despite being under control of a phase variable gene, lgtG, the 2C7 LOS 199 
epitope (Fig. 10A) was expressed by 94% of gonococci recovered directly from cervical 200 
secretions from a cohort of women who attended a sexually transmitted disease (STD) 201 
clinic in Boston (42). We examined a collection of minimally (≤3) passaged isolates 202 
cultured from the female contacts of men with gonorrhea who were referred to a STD 203 
clinic in Nanjing, China, for expression of the 2C7 LOS epitope by whole cell ELISA. We 204 
also examined isolates for their ability to bind to mAb L8 (recognizes an epitope defined 205 
by HepI lactose and phosphoethanolamine [PEA] substitution at the 3-position on HepII; 206 
expression of HepII lactose abrogates mAb L8 binding) and mAb 3F11 (recognizes 207 
terminal [unsialylated] lactosamine of LNnT) (Fig. 10A). As shown in Fig. 10B, each of 208 
75 isolates bound to mAb 2C7, albeit to varying degrees, as did mAb L8 and 3F11. mAb 209 
L1 barely bound to any of the tested isolates.  210 
We next assessed the ability of mAb 2C7 to mediate complement-dependent 211 
bactericidal activity against the first 62 of 75 isolates collected from men with urethritis in 212 
a Nanjing (China) study of gonococcal transmission from men to women. Because 213 
some of the strains were sensitive to killing by 16.7% pooled normal human serum 214 
(NHS) that was used as the complement source, all isolates were grown in media 215 
containing 2 µg/ml CMP-Neu5Ac to render them fully serum resistant (>100% survival). 216 
All (100%) of isolates were killed >50% in the presence of 5 µg/ml of mAb 2C7 and 217 
NHS. This included two of four isolates that bound very low levels of mAb 2C7 by ELISA 218 
(OD450nm between 0.065 and 0.090). Further, serum bactericidal activity correlated with 219 
levels of mAb 2C7 binding (Fig. 10C).   220 
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 The novel finding in this report is the presence of Neu5Ac on N. gonorrhoeae 222 
HepII lactose. To our knowledge, N. gonorrhoeae is the only member of the genus 223 
Neisseria that expresses lactose extending from HepII. Certain N. meningitidis strains 224 
possess lgtG and can substitute Glc at the 3 position of HepII (seen in LOS 225 
immunotypes L2 and L4  (56, 57)), but extensions beyond the proximal Glc in 226 
meningococci have not been described. Prior work by Mandrell et al provided evidence 227 
for the ability of 15253 Lst to sialylate lactose, although not in context of intact bacteria; 228 
LOS in Triton X-100 extracts of strain 15253 (which also contains Lst) could incorporate 229 
radiolabeled Neu5Ac when supplied with exogenous CMP-[14C]-Neu5Ac (58).  230 
 mAb 2C7 recognized 94% of 68 gonococci examined directly from cervical 231 
secretions express and 95% of 101 randomly chosen fresh (second passage) 232 
gonococcal isolates from a sexually transmitted disease clinic in Boston (42). We 233 
recently surveyed 75 minimally passaged gonococcal isolates from Nanjing, China and 234 
noted that 100% of isolates reacted with mAb 2C7. All strains also expressed LNnT, 235 
which suggests that both sialylatable glycans are important for gonococcal 236 
pathogenesis. The importance of LNnT sialylation, both in humans and in the mouse 237 
vaginal colonization model has been established (12, 54, 55, 59). Phase variability of 238 
lgtA and lgtD control expression of LNnT (17). lgtA and lgtC both ‘off’ would result in 239 
expression of lactose, while the combination of lgtA off and lgtC on would result in 240 
elaboration of the PK-like (3-Hex) structure. If lgtA and lgtD are both ‘on’, GalNAc is 241 
added to the terminal Gal of LNnT and prevents sialylation. Sialic acid likely plays a 242 
multifaceted role in Neisserial pathogenesis. In addition to inhibiting complement, 243 
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enhancing resistance to opsonophagocytosis and cationic antimicrobial peptides (60, 244 
61), Neu5Ac engages sialic acid-binding immunoglobulin-type lectins (Siglecs) many of 245 
which are, in turn, linked to an immunoreceptor tyrosine-based inhibition (ITIM) motif 246 
and inhibit the inflammatory response (62). Neu5Ac has also been identified in 247 
gonococcal biofilms (63). Because it can also sialylate HepII lactose, the gonococcus 248 
has the capacity to maintain LOS sialylation even when the previously described 249 
sialylatable LNnT or PK-like structures is not expressed from HepI. While HepII lactose 250 
can be sialylated when HepI also expresses lactose, it is unclear whether HepII lactose 251 
can be sialylated when LNnT or PK is also expressed on HepI. Gilbert and colleagues 252 
showed that meningococcal Lst could add Neu5Ac to 6(5-fluorescein-carboxamido)-253 
hexanoic acid succimidyl ester (FCHASE)-aminophenyl-lactose. Lst added ~6.4-fold or 254 
~3.2-fold more Neu5Ac onto lactosamine (LNnT is lactosamine-lactose) compared to 255 
lactose at substrate concentrations of 0.2 mM or 1.0 mM, respectively (64). Based on 256 
these data, we speculate that LNnT is preferentially sialylated over lactose when both 257 
glycan species are expressed.   258 
 The importance of Neu5Ac on HepII lactose in pathogenesis was illustrated by 259 
attenuation of 15253 Δlst in the mouse vaginal colonization model. Thus, unsialylated 260 
HepII lactose does not support virulence in this model. Expression of HepII lactose by 261 
almost all clinical isolates highlights the importance of maintaining lgtG ‘on’ in vivo. We 262 
are not aware of any naturally occurring gonococcal isolate that lacks lgtG. We have 263 
shown previously that a lgtG deletion mutant of N. gonorrhoeae FA1090 was less 264 
virulent than its wild-type parent (43). Lam and Gray-Owen showed that serial passage 265 
of N. gonorrhoeae in mice resulted an increased fraction of mice infected with each 266 
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subpassage and in a reproducible selection of variants with lgtG ‘on’, providing further 267 
strong evidence of the importance of HepII lactose expression in vivo (65).  268 
We noted that MS11 2-Hex/G- inhibited mouse complement when grown in 269 
CMP-Neu5Ac. The amount of Neu5Ac incorporation onto HepI lactose in this mutant 270 
was likely too small to be detected by shifts on SDS-PAGE or by MS analysis, but was 271 
nevertheless sufficient for functional activity, limited as it was. In contrast, 15253/G-, 272 
which also expresses only lactose from HepI, did not inhibit mouse C3 deposition when 273 
grown in CMP-Neu5Ac-containing media, suggesting that the extent and influence of 274 
HepI lactose sialylation on function may differ across strains. Whether a difference in 275 
HepI lactose sialylation exists between the two strains is unclear despite differences in 276 
function, but could relate to differences in Lst sequence and/or levels of Lst activity. 277 
Translation of DNA sequences of the lst ORF of 15253 and MS11 showed a single 278 
amino acid sequence difference; 15253 possessed a Q (seen in 16 other N. 279 
gonorrhoeae Lst sequences), while MS11 possessed an E (seen in >400 N. 280 
gonorrhoeae Lst sequences) at position 266. The -35/-10 promoter sequence, 281 
transcription start sites and the Shine-Dalgarno sequence were identical in 15253 and 282 
MS11. Packiam et al showed wide variation in lst mRNA levels across gonococcal 283 
strains, but mRNA levels often did not correlate with Lst activity as measured by 284 
sialylation of Triton X-100 bacterial extracts (66).  285 
Linkage of Neu5Ac is a key determinant of its ability to interact with the C-286 
terminus of FH. Blaum and colleagues showed that the interaction between sialic acid 287 
and FH domain 20 is restricted only to α2-3-linked Neu5Ac; α2-6- or α2-8-linked 288 
Neu5Ac do not interact with FH (67). The Neu5Ac-lactose bond is resistant to α2-3 289 
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specific sialidase, suggesting an α2-6 linkage. In accordance with the findings of Blaum 290 
et al, sialylation of HepII lactose – presumably through an α2-6 linkage – did not 291 
increase FH binding to N. gonorrhoeae. We acknowledge that further structural 292 
characterization is necessary to confirm the nature of the Neu5Ac-lactose linkage. How 293 
Neu5Ac on HepII lactose regulates complement remains unclear. Similar to LNnT 294 
sialylation, Neu5Ac linked to LNnT may also inhibit the classical pathway by reducing 295 
binding of IgG directed against select surface targets to the bacterial surface.  296 
Despite similar amounts of mAb 2C7 binding to sialylated compared to 297 
unsialylated 15253, the sialylated derivative was resistant (>50% survival) to mAb 2C7 298 
plus human complement when exposed to CMP-Neu5Ac concentrations ≥3 µg/ml. A 299 
possible explanation is that targets for C4b and C3b on LOS (68), may be obscured by 300 
the presence of Neu5Ac, thereby diminishing Ab efficacy. However, mAb 2C7 remained 301 
effective against 15253 in the mouse vaginal colonization model, where the organism is 302 
sialylated and additional factors such as opsonophagocytosis may contribute to its 303 
bactericidal activity. Mouse FH and C4BP do not bind to gonococci (50, 51). Therefore, 304 
the barrier that mAb 2C7 must surmount to activate complement on gonococci in wild-305 
type mice is likely to be lower than in humans. Ongoing studies have shown efficacy of 306 
mAb 2C7 against wild-type strains MS11 and FA1090, which both bind C4BP and when 307 
sialylated, also bind FH, in ‘dual’ human FH and C4BP transgenic mice (S.G, P.A.R and 308 
S.R, unpublished observations) suggesting that mAb 2C7 can overcome the effects of 309 
these complement inhibitors in vivo.     310 
In conclusion, this novel site of sialylation on N. gonorrhoeae HepII lactose can 311 
inhibit complement activation and also engage Siglecs (45). These findings also explain 312 
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the ubiquitous expression of HepII lactose (an integral part of the ‘2C7 LOS epitope’) 313 
among clinical isolates of N. gonorrhoeae and further validate targeting the 2C7 epitope 314 
with antibody-based vaccines and immunotherapeutics.    315 
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Materials and Methods 316 
 317 
Bacterial strains. Strain 15253 was recovered from an individual with 318 
disseminated gonococcal infection and has been described previously (44). Only lgtA 319 
and lgtE are intact in its lgtA-E locus (69). Deletion of lgtG in 15253 to yield 15253/G- 320 
has been described previously (70). Deletion of LOS sialyltransferase (lst) to yield 321 
15253 Δlst (lst::kanR) was performed as described previously (54). All the LOS mutant 322 
derivatives of MS11 have been described previously (48). The LOS phenotypes of 323 
15253, 15253/G- and the MS11 mutants used in this study are listed in Figure 1. 324 
Seventy five additional isolates were obtained from subjects enrolled in a transmission 325 
study (Ref.) of gonococcal infection from men to women in Nanjing, China. All subjects 326 
provided written informed consent in accordance with requirements by Institutional 327 
Review Boards from: the University of Massachusetts Medical School; Boston 328 
Univeristy School of Medicine and  the Institute of Dermatology, Chinese Academy of 329 
Medical Sciences & Peking Union Medical College, Nanjing, China.  330 
 331 
Normal human serum. Serum was obtained from normal healthy adult 332 
volunteers with no history of gonococcal or meningococcal infection who provided 333 
informed consent. Participation was approved by the University of Massachusetts 334 
Institutional Review Board for the protection of human subjects. Serum was obtained 335 
from whole blood that was clotted at 25 °C for 30 min followed by centrifugation at 1500 336 
g for 20 min at 4 °C. Serum from 10 donors was pooled, aliquoted and stored at -80 °C.  337 
 338 
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Mouse complement. Use of animals in this study was performed in strict 339 
accordance with the recommendations in the Guide for the Care and Use of Laboratory 340 
Animals of the National Institutes of Health. The protocol was approved by the 341 
Institutional Animal Care and Use Committee (IACUC) at the University of 342 
Massachusetts Medical School. Mouse blood obtained by terminal cardiac puncture 343 
was allowed to clot for 20 min at room temperature, then placed on ice for 20 min and 344 
centrifuged at 10,000 g for 10 min at 4 °C. Serum was harvested and stored in single-345 
use aliquots at -80 °C.  346 
 347 
Flow cytometry. Factor H binding to N. gonorrhoeae was detected as described 348 
previously (71). Briefly, ~107 bacteria in HBSS containing 1 mM CaCl2 and 1 mM MgCl2 349 
(HBSS++) containing 0.1% BSA was incubated with 10 µg/ml purified human FH 350 
(Complement Technologies, Inc.) for 15 min at 37 °C. Bacteria-bound FH was detected 351 
with goat anti-human FH (1 µg/ml) (Complement Technologies, Inc.), followed by anti-352 
goat IgG FITC (Sigma) at a dilution of 1:100. Bacteria were fixed in 1% 353 
paraformaldehyde in PBS and Data were acquired on a FACSCalibur flow cytometer 354 
and analyzed using FlowJo software. 355 
Mouse C3 deposition on bacteria was measured by incubating 107 CFU of 356 
bacteria in HBSS++/BSA with mouse complement (concentration stated for each 357 
experiment) for 20 min at 37 °C. Mouse C3 fragments deposited on bacteria were 358 
detected using anti-mouse IgG FITC (MP Biomedicals) at a dilution of 1:100, and flow 359 
cytometry was performed as described above.  360 
 361 
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SDS-PAGE. LOS in Protease K (Calbiochem)-treated bacterial lysates prepared 362 
as described previously (48) in Tricine-SDS Sample Buffer (Boston Biomolecules) was 363 
visualized by electrophoresis on CriterionTM 16% Tris-Tricine gels (Bio-Rad) using Tris-364 
Tricine-SDS Cathode buffer (Boston Biomolecules) at 100 V at 4 °C followed by silver 365 
staining (Bio-Rad Silver Stain kit).  366 
 367 
Neuraminidase treatment. Desialylation was carried out with α2-3-specific 368 
neuraminidase (New England Biolabs; Cat. No. P0743S). Approximately 107 bacteria in 369 
GlycoBuffer 1 (New England Biolabs) were treated with 16 U neuraminidase (reaction 370 
volume 100 µl) for 1 h at 37 °C. Control reactions contained buffer alone. Bacteria were 371 
then incubated with mouse serum as described above to measure quantitatively, C3 372 
deposition.  373 
 374 
Serum bactericidal assay. Strain 15253 was grown in gonococcal liquid media 375 
(Morse A, Morse B and IsoVitaleXTM (72)) containing CMP-Neu5Ac at concentrations 376 
ranging from 0 to 100 µg/ml in half-log10 increments; susceptibility to mAb 2C7 (5 µg/ml) 377 
was determined by serum bactericidal assay as described previously (72) with minor 378 
modifications. The clinical isolates from Nanjing, China were all grown in liquid media as 379 
described above, supplemented with 2 µg/ml of CMP-Neu5Ac. Approximately 2000 380 
CFU gonococci in HBSS++/0.1% BSA were incubated with 20% NHS either in the 381 
presence or absence of mAb 2C7. Final bactericidal reaction volumes were maintained 382 
at 75 μl. Aliquots of 12.5 μl were plated onto chocolate agar plates in duplicate at the 383 
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beginning of the assay (t0) and again after incubation at 37°C for 30 min (t30). Survival 384 
was calculated as the number of viable colonies at t30 relative to t0. 385 
 386 
Mass spectroscopic analysis of LOS. O-deacylated LOS was prepared as 387 
described previously (26). LC-MS was performed using a Waters Premier Q-TOF 388 
operated in the positive-ion mode with an Agilent 1260 capillary LC system. LC 389 
separation was done on an Agilent Eclipse XDB C8 column (5m, 50 x 1mm) operated 390 
at 55 ºC. The flow rate was 20 L/min. Solvent A: aqueous 0.2 % formic acid/0.028 % 391 
ammonia; solvent B: Isopropanol with 0.2% formic acid/0.028% ammonia. The following 392 
gradient was used: 0-2 min. 10 % B, 2-16 min linear gradient to 85 % B, 16-25 min. 85 393 
%B, 25-30 min. equilibration at 10% B. 394 
 395 
Anti-LOS mAbs. Anti-LOS mAbs 3F11 (73), L8 (74), L1 (75) and 2C7 (42) have 396 
been described previously. Fig. 10A indicates the specificities of each of the mAbs  397 
 398 
Whole cell ELISA. Whole cell ELISA was performed as described previously 399 
(71). Briefly, U-bottomed microtiter wells (Dynatech Laboratories, Inc., Chantilly, VA) 400 
were coated with 50 µl of bacterial suspensions (~108 organisms/ml) in PBS for 3 h at 401 
37 °C, followed by incubation overnight at 4 °C. Plates were washed with PBS 402 
containing 0.05% Tween 20. Tissue culture supernatants containing mAbs 3F11, L8, L1 403 
and 2C7 were dispensed into wells and incubated for 1 h at 37 °C, followed by washing 404 
with PBS/0.05% Tween 20. Bound 2C7, L8 and L1 were disclosed with anti-mouse IgG 405 
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alkaline phosphatase (Sigma), and mAb 3F11 was detected with anti-mouse IgM 406 
alkaline phosphatase (Sigma).  407 
 408 
Cmah KO mice. Unlike mice, humans lack the ability to convert Neu5Ac to 409 
Neu5Gc, because of an Alu-mediated deletion in a critical exon that encodes the 410 
enzyme, CMP-Neu5Ac hydroxylase (CMAH) (76). Deletion of Cmah in mice results in 411 
expression of only Neu5Ac. Cmah knockout (KO) mice were generated with a human-412 
like deletion in exon 6 of Cmah as described previously (77) and were subsequently 413 
back-crossed >10 generations into a BALB/c background.   414 
 415 
Mouse infection.  The mouse vaginal colonization model developed by Jerse 416 
was used (78). Briefly, female Cmah KO mice in the diestrus phase of the estrous cycle 417 
were started on treatment (that day) with 0.1 mg Premarin® (Pfizer) in 200 µl of water 418 
given subcutaneously on each of three days; −2, 0 and +2 days (before, the day of and 419 
after inoculation) to prolong the estrus phase of the reproductive cycle and promote 420 
susceptibility to Ng infection.  Antibiotics (vancomycin, colistin, neomycin, trimethoprim 421 
and streptomycin (VCNTS)) ineffective against N. gonorrhoeae were also used to 422 
reduce competitive microflora (7).  Mice (n=10/group) were infected on Day 0 with either 423 
strain 15253, 15253/G- or 15253 Δlst (inoculum specified for each experiment).  424 
Vaginas were swabbed daily and plated on chocolate agar containing VCNTS to 425 
enumerate N. gonorrhoeae CFUs. The efficacy of mAb 2C7 in vivo against 15253 was 426 
performed in wild-type BALB/c mice (Jackson Laboratories) as described previously. 427 
Mice were treated with mAb 2C7 or control mouse IgG3 intraperitoneally, 10 µg twice a 428 
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day on days -2, -1 (prior to) and 0 (the day of infection with strain 15253 and daily 429 
vaginal CFU enumeration was carried out as described above.  430 
 431 
Statistical analyses. Experiments that compared clearance of N. gonorrhoeae in 432 
independent groups of mice estimated and tested three characteristics of the data (43): 433 
Time to clearance, longitudinal trends in mean log10 CFU and the cumulative CFU as 434 
area under the curve (AUC). Statistical analyses were performed using mice that initially 435 
yielded bacterial colonies on Days 1 and/or 2.  Median time to clearance was estimated 436 
using Kaplan-Meier survival curves; times to clearance were compared between groups 437 
using the Mantel-Cox log-rank test. Mean log10 CFU trends over time were compared 438 
between groups using a linear mixed model with mouse as the random effect using both 439 
a random intercept and a random slope. A cubic function in time was determined to 440 
provide the best fit; random slopes were linear in time. A likelihood ratio test was used 441 
to compare nested models (with and without the interaction term of group and time) to 442 
test whether the trend differed over time between the two groups. The mean AUC (log10 443 
CFU versus time) was computed for each mouse to estimate the bacterial burden over 444 
time (cumulative infection); the means under the curves were compared between 445 
groups using the nonparametric two-sample Wilcoxon rank-sum (Mann-Whitney) test 446 
because distributions were skewed or kurtotic. The Kruskal-Wallis equality-of-447 
populations rank test was also applied to compare more than two groups in an 448 
experiment. Correlation between survival in serum bactericidal assays and mAb 2C7 449 
binding was performed by Spearman’s non-parametric test. A cubic equation as used to 450 
generate the best-fit curve.   451 
.CC-BY-NC-ND 4.0 International licensepeer-reviewed) is the author/funder. It is made available under a




We thank Nancy Nowak and Samuel Fountain for technical assistance. This work was 453 
supported by grants from the National Institutes of Health / National Institutes of Allergy 454 
and Infectious Diseases, AI118161 (to S.R.), AI114790, AI132296 (to P.A.R and S.R.) 455 
and AI114710 (to P.A.R. and S.G.).    456 
.CC-BY-NC-ND 4.0 International licensepeer-reviewed) is the author/funder. It is made available under a
The copyright holder for this preprint (which was not. http://dx.doi.org/10.1101/302968doi: bioRxiv preprint first posted online Apr. 17, 2018; 
23 
 
References  457 
1. Newman L, Rowley J, Vander Hoorn S, Wijesooriya NS, Unemo M, Low N, 458 
Stevens G, Gottlieb S, Kiarie J, Temmerman M. 2015. Global Estimates of the 459 
Prevalence and Incidence of Four Curable Sexually Transmitted Infections in 460 
2012 Based on Systematic Review and Global Reporting. PLoS One 461 
10:e0143304. 462 
2. Camara J, Serra J, Ayats J, Bastida T, Carnicer-Pont D, Andreu A, Ardanuy C. 463 
2012. Molecular characterization of two high-level ceftriaxone-resistant Neisseria 464 
gonorrhoeae isolates detected in Catalonia, Spain. J Antimicrob Chemother 465 
67:1858-60. 466 
3. Lahra MM, Ryder N, Whiley DM. 2014. A new multidrug-resistant strain of 467 
Neisseria gonorrhoeae in Australia. N Engl J Med 371:1850-1. 468 
4. Ohnishi M, Golparian D, Shimuta K, Saika T, Hoshina S, Iwasaku K, Nakayama 469 
S, Kitawaki J, Unemo M. 2011. Is Neisseria gonorrhoeae initiating a future era of 470 
untreatable gonorrhea?: detailed characterization of the first strain with high-level 471 
resistance to ceftriaxone. Antimicrob Agents Chemother 55:3538-45. 472 
5. Unemo M, Shafer WM. 2014. Antimicrobial resistance in Neisseria gonorrhoeae 473 
in the 21st century: past, evolution, and future. Clin Microbiol Rev 27:587-613. 474 
6. Katz AR, Komeya AY, Kirkcaldy RD, Whelen AC, Soge OO, Papp JR, Kersh EN, 475 
Wasserman GM, O'Connor NP, O'Brien PS, Sato DT, Maningas EV, Kunimoto 476 
GY, Tomas JE. 2017. Cluster of Neisseria gonorrhoeae Isolates With High-level 477 
Azithromycin Resistance and Decreased Ceftriaxone Susceptibility, Hawaii, 478 
2016. Clin Infect Dis 65:918-923. 479 
7. Jerse AE, Wu H, Packiam M, Vonck RA, Begum AA, Garvin LE. 2011. Estradiol-480 
Treated Female Mice as Surrogate Hosts for Neisseria gonorrhoeae Genital 481 
Tract Infections. Front Microbiol 2:107. 482 
8. Apicella MA, Mandrell RE. 1989. Molecular mimicry as a factor in the 483 
pathogenesis of human neisserial infections: in vitro and in vivo modification of 484 
the lipooligosaccharide of Neisseria gonorrhoeae by N-acetylneuraminic acid. 485 
Pediatr Infect Dis J 8:901-2. 486 
9. Balthazar JT, Gusa A, Martin LE, Choudhury B, Carlson R, Shafer WM. 2011. 487 
Lipooligosaccharide Structure is an Important Determinant in the Resistance of 488 
Neisseria Gonorrhoeae to Antimicrobial Agents of Innate Host Defense. Front 489 
Microbiol 2:30. 490 
10. Blake MS, Blake CM, Apicella MA, Mandrell RE. 1995. Gonococcal opacity: 491 
lectin-like interactions between Opa proteins and lipooligosaccharide. Infect 492 
Immun 63:1434-1439. 493 
11. Edwards JL, Apicella MA. 2002. The role of lipooligosaccharide in Neisseria 494 
gonorrhoeae pathogenesis of cervical epithelia: lipid A serves as a C3 acceptor 495 
molecule. Cell Microbiol 4:585-98. 496 
12. Schneider H, Griffiss JM, Boslego JW, Hitchcock PJ, Zahos KM, Apicella MA. 497 
1991. Expression of paragloboside-like lipooligosaccharides may be a necessary 498 
component of gonococcal pathogenesis in men. J Exp Med 174:1601-1605. 499 
13. Schneider H, Griffiss JM, Mandrell RE, Jarvis GA. 1985. Elaboration of a 3.6-500 
kilodalton lipooligosaccharide, antibody against which is absent from human 501 
.CC-BY-NC-ND 4.0 International licensepeer-reviewed) is the author/funder. It is made available under a
The copyright holder for this preprint (which was not. http://dx.doi.org/10.1101/302968doi: bioRxiv preprint first posted online Apr. 17, 2018; 
24 
 
sera, is associated with serum resistance of Neisseria gonorrhoeae. Infect 502 
Immun 50:672-677. 503 
14. Song W, Ma L, Chen R, Stein DC. 2000. Role of lipooligosaccharide in Opa-504 
independent invasion of Neisseria gonorrhoeae into human epithelial cells. J Exp 505 
Med 191:949-60. 506 
15. van Vliet SJ, Steeghs L, Bruijns SC, Vaezirad MM, Snijders Blok C, Arenas 507 
Busto JA, Deken M, van Putten JP, van Kooyk Y. 2009. Variation of Neisseria 508 
gonorrhoeae lipooligosaccharide directs dendritic cell-induced T helper 509 
responses. PLoS Pathog 5:e1000625. 510 
16. Wetzler LM, Barry K, Blake MS, Gotschlich EC. 1992. Gonococcal 511 
lipooligosaccharide sialylation prevents complement- dependent killing by 512 
immune sera. Infect Immun 60:39-43. 513 
17. Yang QL, Gotschlich EC. 1996. Variation of gonococcal lipooligosaccharide 514 
structure is due to alterations in poly-G tracts in lgt genes encoding glycosyl 515 
transferases. J Exp Med 183:323-7. 516 
18. Zhang P, Schwartz O, Pantelic M, Li G, Knazze Q, Nobile C, Radovich M, He J, 517 
Hong SC, Klena J, Chen T. 2006. DC-SIGN (CD209) recognition of Neisseria 518 
gonorrhoeae is circumvented by lipooligosaccharide variation. J Leukoc Biol 519 
79:731-8. 520 
19. Patrone JB, Stein DC. 2007. Effect of gonococcal lipooligosaccharide variation 521 
on human monocytic cytokine profile. BMC Microbiol 7:7. 522 
20. Mandrell RE, Apicella MA. 1993. Lipo-oligosaccharides (LOS) of mucosal 523 
pathogens: molecular mimicry and host-modification of LOS. Immunobiology 524 
187:382-402. 525 
21. Mandrell RE, Griffiss JM, Macher BA. 1988. Lipooligosaccharides (LOS) of 526 
Neisseria gonorrhoeae and Neisseria meningitidis have components that are 527 
immunochemically similar to precursors of human blood group antigens. 528 
Carbohydrate sequence specificity of the mouse monoclonal antibodies that 529 
recognize crossreacting antigens on LOS and human erythrocytes. J Exp Med 530 
168:107-26. 531 
22. Mandrell RE. 1992. Further antigenic similarities of Neisseria gonorrhoeae 532 
lipooligosaccharides and human glycosphingolipids. Infect Immun 60:3017-3020. 533 
23. Parsons NJ, Constantinidou C, Cole JA, Smith H. 1994. Sialylation of 534 
lipopolysaccharide by CMP-NANA in viable gonococci is enhanced by low Mr 535 
material released from blood cell extracts but not by some UDP sugars. Microb 536 
Pathog 16:413-21. 537 
24. Smith H, Parsons NJ, Cole JA. 1995. Sialylation of neisserial lipopolysaccharide: 538 
a major influence on pathogenicity. Microb Pathog 19:365-77. 539 
25. Wakarchuk WW, Watson D, St Michael F, Li J, Wu Y, Brisson JR, Young NM, 540 
Gilbert M. 2001. Dependence of the bi-functional nature of a sialyltransferase 541 
from Neisseria meningitidis on a single amino acid substitution. J Biol Chem 542 
276:12785-90. 543 
26. Gulati S, Cox A, Lewis LA, Michael FS, Li J, Boden R, Ram S, Rice PA. 2005. 544 
Enhanced factor H binding to sialylated Gonococci is restricted to the sialylated 545 
lacto-N-neotetraose lipooligosaccharide species: implications for serum 546 
.CC-BY-NC-ND 4.0 International licensepeer-reviewed) is the author/funder. It is made available under a
The copyright holder for this preprint (which was not. http://dx.doi.org/10.1101/302968doi: bioRxiv preprint first posted online Apr. 17, 2018; 
25 
 
resistance and evidence for a bifunctional lipooligosaccharide sialyltransferase in 547 
Gonococci. Infect Immun 73:7390-7. 548 
27. Nairn CA, Cole JA, Patel PV, Parsons NJ, Fox JE, Smith H. 1988. Cytidine 5'-549 
monophospho-N-acetylneuraminic acid or a related compound is the low Mr 550 
factor from human red blood cells which induces gonococcal resistance to killing 551 
by human serum. J Gen Microbiol 134:3295-306. 552 
28. Elkins C, Carbonetti NH, Varela VA, Stirewalt D, Klapper DG, Sparling PF. 1992. 553 
Antibodies to N-terminal peptides of gonococcal porin are bactericidal when 554 
gonococcal lipopolysaccharide is not sialylated. Mol Microbiol 6:2617-28. 555 
29. Ram S, Sharma AK, Simpson SD, Gulati S, McQuillen DP, Pangburn MK, Rice 556 
PA. 1998. A novel sialic acid binding site on factor H mediates serum resistance 557 
of sialylated Neisseria gonorrhoeae. J Exp Med 187:743-752. 558 
30. Bergfeld AK, Claus H, Vogel U, Muhlenhoff M. 2007. Biochemical 559 
characterization of the polysialic acid specific O-acetyltransferase NeuO of 560 
Escherichia coli K1. J Biol Chem. 561 
31. Blacklow RS, Warren L. 1962. Biosynthesis of sialic acids by Neisseria 562 
meningitidis. J Biol Chem 237:3520-6. 563 
32. Edwards MS, Kasper DL, Jennings HJ, Baker CJ, Nicholson-Weller A. 1982. 564 
Capsular sialic acid prevents activation of the alternative complement pathway by 565 
type III group B streptococci. J Immunol 128:1278-1283. 566 
33. Markham RB, Nicholson-Weller A, Schiffman G, Kasper DL. 1982. The presence 567 
of sialic acid on two related bacterial polysaccharides determines the site of the 568 
primary immune response and the effect of complement depletion on the 569 
response in mice. J Immunol 128:2731-2733. 570 
34. Ourth DD, Bachinski LM. 1987. Bacterial sialic acid modulates activation of the 571 
alternative complement pathway of channel catfish (Ictalurus punctatus). Dev 572 
Comp Immunol 11:551-64. 573 
35. Severi E, Randle G, Kivlin P, Whitfield K, Young R, Moxon R, Kelly D, Hood D, 574 
Thomas GH. 2005. Sialic acid transport in Haemophilus influenzae is essential 575 
for lipopolysaccharide sialylation and serum resistance and is dependent on a 576 
novel tripartite ATP-independent periplasmic transporter. Mol Microbiol 58:1173-577 
85. 578 
36. Silver RP, Vimr ER. 1990. Polysialic acid capsule of Escherichia coli K1, p 39-60. 579 
In Iglewski B, Clark V (ed), The Bacteria, vol XI. Academc Press, Inc., New York. 580 
37. Tomlinson S, Pontes de Carvalho LC, Vandekerckhove F, Nussenzweig V. 1994. 581 
Role of sialic acid in the resistance of Trypanosoma cruzi trypomastigotes to 582 
complement. J Immunol 153:3141-3147. 583 
38. Vogel U, Hammerschmidt S, Frosch M. 1996. Sialic acids of both the capsule 584 
and the sialylated lipooligosaccharide of Neisseria meningitis serogroup B are 585 
prerequisites for virulence of meningococci in the infant rat. Med Microbiol 586 
Immunol (Berl) 185:81-7. 587 
39. Li Y, Yu H, Cao H, Muthana S, Chen X. 2012. Pasteurella multocida CMP-sialic 588 
acid synthetase and mutants of Neisseria meningitidis CMP-sialic acid 589 
synthetase with improved substrate promiscuity. Appl Microbiol Biotechnol 590 
93:2411-23. 591 
.CC-BY-NC-ND 4.0 International licensepeer-reviewed) is the author/funder. It is made available under a
The copyright holder for this preprint (which was not. http://dx.doi.org/10.1101/302968doi: bioRxiv preprint first posted online Apr. 17, 2018; 
26 
 
40. Avril T, Wagner ER, Willison HJ, Crocker PR. 2006. Sialic acid-binding 592 
immunoglobulin-like lectin 7 mediates selective recognition of sialylated glycans 593 
expressed on Campylobacter jejuni lipooligosaccharides. Infect Immun 74:4133-594 
41. 595 
41. Hirsch RL, Griffin DE, Winkelstein JA. 1981. Host modification of Sindbis virus 596 
sialic acid content influences alternative complement pathway activation and 597 
virus clearance. J Immunol 127:1740-3. 598 
42. Gulati S, McQuillen DP, Mandrell RE, Jani DB, Rice PA. 1996. Immunogenicity of 599 
Neisseria gonorrhoeae lipooligosaccharide epitope 2C7, widely expressed in vivo 600 
with no immunochemical similarity to human glycosphingolipids [published 601 
erratum appears in J Infect Dis 1997 Apr;175(4):1027]. J Infect Dis 174:1223-37. 602 
43. Gulati S, Zheng B, Reed GW, Su X, Cox AD, St Michael F, Stupak J, Lewis LA, 603 
Ram S, Rice PA. 2013. Immunization against a Saccharide Epitope Accelerates 604 
Clearance of Experimental Gonococcal Infection. PLoS Pathog 9:e1003559. 605 
44. Yamasaki R, Kerwood DE, Schneider H, Quinn KP, Griffiss JM, Mandrell RE. 606 
1994. The structure of lipooligosaccharide produced by Neisseria gonorrhoeae, 607 
strain 15253, isolated from a patient with disseminated infection:  evidence for a 608 
new glycosylation pathway of gonococcal lipooligosaccharide. J Biol Chem 609 
269:30345-30351. 610 
45. Landig CS, Fong J, Hazel A, Agarwal S, Schwarz F, Massari P, Nizet V, S. R, 611 
Varki A. 2016. The human-specific pathogen Neisseria gonorrhoeae engages 612 
innate immunoregulatory Siglec receptors in a species-specific manner. 20th 613 
International Pathogenic Neisseria Conference, Manchester, UK. p 172.   614 
46. Brinkman-Van der Linden EC, Angata T, Reynolds SA, Powell LD, Hedrick SM, 615 
Varki A. 2003. CD33/Siglec-3 binding specificity, expression pattern, and 616 
consequences of gene deletion in mice. Mol Cell Biol 23:4199-206. 617 
47. Crocker PR, Paulson JC, Varki A. 2007. Siglecs and their roles in the immune 618 
system. Nat Rev Immunol 7:255-66. 619 
48. Chakraborti S, Lewis LA, Cox AD, St Michael F, Li J, Rice PA, Ram S. 2016. 620 
Phase-Variable Heptose I Glycan Extensions Modulate Efficacy of 2C7 Vaccine 621 
Antibody Directed against Neisseria gonorrhoeae Lipooligosaccharide. J 622 
Immunol 196:4576-86. 623 
49. Ram S, McQuillen DP, Gulati S, Elkins C, Pangburn MK, Rice PA. 1998. Binding 624 
of complement factor H to loop 5 of porin protein 1A: a molecular mechanism of 625 
serum resistance of nonsialylated Neisseria gonorrhoeae. J Exp Med 188:671-626 
680. 627 
50. Ngampasutadol J, Ram S, Blom AM, Jarva H, Jerse AE, Lien E, Goguen J, 628 
Gulati S, Rice PA. 2005. Human C4b-binding protein selectively interacts with 629 
Neisseria gonorrhoeae and results in species-specific infection. Proc Natl Acad 630 
Sci U S A 102:17142-7. 631 
51. Ngampasutadol J, Ram S, Gulati S, Agarwal S, Li C, Visintin A, Monks B, Madico 632 
G, Rice PA. 2008. Human Factor H Interacts Selectively with Neisseria 633 
gonorrhoeae and Results in Species-Specific Complement Evasion. J Immunol 634 
180:3426-35. 635 
52. Gulati S, Schoenhofen IC, B. Z, Unemo M, Landig CS, Reed GW, Varki A, Rice 636 
PA, Ram S. 2016. A sialic acid analog attenuates gonococcal infection in mice 637 
.CC-BY-NC-ND 4.0 International licensepeer-reviewed) is the author/funder. It is made available under a
The copyright holder for this preprint (which was not. http://dx.doi.org/10.1101/302968doi: bioRxiv preprint first posted online Apr. 17, 2018; 
27 
 
that express exclusively human-like sialic acid that enhances the burden of 638 
infection, p. In (ed),   639 
53. Yamasaki R, Koshino H, Kurono S, Nishinaka Y, McQuillen DP, Kume A, Gulati 640 
S, Rice PA. 1999. Structural and immunochemical characterization of a Neisseria 641 
gonorrhoeae epitope defined by a monoclonal antibody 2C7; the antibody 642 
recognizes a conserved epitope on specific lipo-oligosaccharides in spite of the 643 
presence of human carbohydrate epitopes. J Biol Chem 274:36550-8. 644 
54. Lewis LA, Gulati S, Burrowes E, Zheng B, Ram S, Rice PA. 2015. alpha-2,3-645 
Sialyltransferase Expression Level Impacts the Kinetics of Lipooligosaccharide 646 
Sialylation, Complement Resistance, and the Ability of Neisseria gonorrhoeae to 647 
Colonize the Murine Genital Tract. MBio 6:e02465-14. 648 
55. Wu H, Jerse AE. 2006. Alpha-2,3-sialyltransferase enhances Neisseria 649 
gonorrhoeae survival during experimental murine genital tract infection. Infect 650 
Immun 74:4094-103. 651 
56. Kogan G, Uhrin D, Brisson JR, Jennings HJ. 1997. Structural basis of the 652 
Neisseria meningitidis immunotypes including the L4 and L7 immunotypes. 653 
Carbohydr Res 298:191-9. 654 
57. Rahman MM, Stephens DS, Kahler CM, Glushka J, Carlson RW. 1998. The 655 
lipooligosaccharide (LOS) of Neisseria meningitidis serogroup B strain NMB 656 
contains L2, L3, and novel oligosaccharides, and lacks the lipid-A 4'-phosphate 657 
substituent. Carbohydr Res 307:311-24. 658 
58. Mandrell RE, Griffiss JM, Smith H, Cole JA. 1993. Distribution of a 659 
lipooligosaccharide-specific sialyltransferase in pathogenic and non-pathogenic 660 
Neisseria. Microb Pathog 14:315-27. 661 
59. Schneider H, Cross AS, Kuschner RA, Taylor DN, Sadoff JC, Boslego JW, Deal 662 
CD. 1995. Experimental human gonococcal urethritis: 250 Neisseria 663 
gonorrhoeae MS11mkC are infective. J Infect Dis 172:180-5. 664 
60. Wu H, Shafer WM, Jerse AE. 2012. Relative importance of LOS sialylation and 665 
the MtrC-MtrD-MtrE active efflux pump in gonococcal evasion of host innate 666 
defenses, abstr XVIIIth International Pathogenic Neisseria Conference, 667 
Wuerzburg, Germany,  668 
61. Wu H, Jerse AE. Sialylation Protects Intracellular Neisseria gonorrhoeae from 669 
Nonoxidative Killing by Polymorphonuclear Leukocytes and Antimicrobial 670 
Peptides, p 126. In (ed),   671 
62. Jones C, Virji M, Crocker PR. 2003. Recognition of sialylated meningococcal 672 
lipopolysaccharide by siglecs expressed on myeloid cells leads to enhanced 673 
bacterial uptake. Mol Microbiol 49:1213-25. 674 
63. Greiner LL, Edwards JL, Shao J, Rabinak C, Entz D, Apicella MA. 2005. Biofilm 675 
Formation by Neisseria gonorrhoeae. Infect Immun 73:1964-70. 676 
64. Gilbert M, Watson DC, Cunningham AM, Jennings MP, Young NM, Wakarchuk 677 
WW. 1996. Cloning of the lipooligosaccharide alpha-2,3-sialyltransferase from 678 
the bacterial pathogens Neisseria meningitidis and Neisseria gonorrhoeae. J Biol 679 
Chem 271:28271-6. 680 
65. Lam J, Gray-Owen SD. Genetic adaptation contributing to increased gonococcal 681 
fitness during vaginal infection of CEACAM-humanized mice, p 24. In (ed),   682 
.CC-BY-NC-ND 4.0 International licensepeer-reviewed) is the author/funder. It is made available under a
The copyright holder for this preprint (which was not. http://dx.doi.org/10.1101/302968doi: bioRxiv preprint first posted online Apr. 17, 2018; 
28 
 
66. Packiam M, Shell DM, Liu SV, Liu YB, McGee DJ, Srivastava R, Seal S, Rest 683 
RF. 2006. Differential expression and transcriptional analysis of the alpha-2,3-684 
sialyltransferase gene in pathogenic Neisseria spp. Infect Immun 74:2637-50. 685 
67. Blaum BS, Hannan JP, Herbert AP, Kavanagh D, Uhrin D, Stehle T. 2015. 686 
Structural basis for sialic acid-mediated self-recognition by complement factor H. 687 
Nat Chem Biol 11:77-83. 688 
68. Lewis LA, Ram S, Prasad A, Gulati S, Getzlaff S, Blom AM, Vogel U, Rice PA. 689 
2008. Defining targets for complement components C4b and C3b on the 690 
pathogenic neisseriae. Infect Immun 76:339-50. 691 
69. Erwin AL, Haynes PA, Rice PA, Gotschlich EC. 1996. Conservation of the 692 
lipooligosaccharide synthesis locus lgt among strains of Neisseria gonorrhoeae: 693 
requirement for lgtE in synthesis of the 2C7 epitope and of the beta chain of 694 
strain 15253. J Exp Med 184:1233-41. 695 
70. Ngampasutadol J, Rice PA, Walsh MT, Gulati S. 2006. Characterization of a 696 
peptide vaccine candidate mimicking an oligosaccharide epitope of Neisseria 697 
gonorrhoeae and resultant immune responses and function. Vaccine 24:157-70. 698 
71. Gulati S, Schoenhofen IC, Whitfield DM, Cox AD, Li J, St Michael F, Vinogradov 699 
EV, Stupak J, Zheng B, Ohnishi M, Unemo M, Lewis LA, Taylor RE, Landig CS, 700 
Diaz S, Reed GW, Varki A, Rice PA, Ram S. 2015. Utilizing CMP-Sialic Acid 701 
Analogs to Unravel Neisseria gonorrhoeae Lipooligosaccharide-Mediated 702 
Complement Resistance and Design Novel Therapeutics. PLoS Pathogens 703 
11:e1005290. 704 
72. McQuillen DP, Gulati S, Rice PA. 1994. Complement-mediated bacterial killing 705 
assays. Methods Enzymol 236:137-47. 706 
73. Apicella MA, Mandrell RE, Shero M, Wilson M, Griffiss JM, Brooks GF, Fenner C, 707 
Breen CF, Rice PA. 1990. Modification by sialic acid of Neisseria gonorrhoeae 708 
lipooligosaccharide epitope expression in human urethral exudates: an 709 
immunoelectron microscopic analysis. J Infect Dis 162:506-512. 710 
74. O'Connor ET, Swanson KV, Cheng H, Fluss K, Griffiss JM, Stein DC. 2008. 711 
Structural requirements for monoclonal antibody 2-1-L8 recognition of neisserial 712 
lipooligosaccharides. Hybridoma (Larchmt) 27:71-9. 713 
75. McLeod Griffiss J, Brandt BL, Saunders NB, Zollinger W. 2000. Structural 714 
relationships and sialylation among meningococcal L1, L8, and L3,7 715 
lipooligosaccharide serotypes. J Biol Chem 275:9716-24. 716 
76. Chou HH, Takematsu H, Diaz S, Iber J, Nickerson E, Wright KL, Muchmore EA, 717 
Nelson DL, Warren ST, Varki A. 1998. A mutation in human CMP-sialic acid 718 
hydroxylase occurred after the Homo-Pan divergence. Proc Natl Acad Sci U S A 719 
95:11751-6. 720 
77. Hedlund M, Tangvoranuntakul P, Takematsu H, Long JM, Housley GD, 721 
Kozutsumi Y, Suzuki A, Wynshaw-Boris A, Ryan AF, Gallo RL, Varki N, Varki A. 722 
2007. N-glycolylneuraminic acid deficiency in mice: implications for human 723 
biology and evolution. Mol Cell Biol 27:4340-6. 724 
78. Jerse AE. 1999. Experimental gonococcal genital tract infection and opacity 725 
protein expression in estradiol-treated mice. Infect Immun 67:5699-708. 726 
79. Varki A, Cummings RD, Aebi M, Packer NH, Seeberger PH, Esko JD, Stanley P, 727 
Hart G, Darvill A, Kinoshita T, Prestegard JJ, Schnaar RL, Freeze HH, Marth JD, 728 
.CC-BY-NC-ND 4.0 International licensepeer-reviewed) is the author/funder. It is made available under a
The copyright holder for this preprint (which was not. http://dx.doi.org/10.1101/302968doi: bioRxiv preprint first posted online Apr. 17, 2018; 
29 
 
Bertozzi CR, Etzler ME, Frank M, Vliegenthart JF, Lutteke T, Perez S, Bolton E, 729 
Rudd P, Paulson J, Kanehisa M, Toukach P, Aoki-Kinoshita KF, Dell A, 730 
Narimatsu H, York W, Taniguchi N, Kornfeld S. 2015. Symbol Nomenclature for 731 
Graphical Representations of Glycans. Glycobiology 25:1323-4. 732 
  733 
.CC-BY-NC-ND 4.0 International licensepeer-reviewed) is the author/funder. It is made available under a
The copyright holder for this preprint (which was not. http://dx.doi.org/10.1101/302968doi: bioRxiv preprint first posted online Apr. 17, 2018; 
30 
 
Figure Legends 734 
Fig. 1. LOS glycan extensions from heptose (Hep) I and HepII elaborated by N. 735 
gonorrhoeae strains used in this study. Glycan extensions from HepI and HepII of the 736 
major LOS structure represented by the strains is shown using the symbol 737 
nomenclature for graphical representation of individual glycans (79). N. gonorrhoeae 738 
lack the ability to produce CMP-Neu5Ac, therefore capping of LOS with Neu5Ac 739 
requires the addition of CMP-Neu5Ac to growth media.  740 
 741 
Fig. 2. Evidence of sialylation of HepII lactose on N. gonorrhoeae 15253 and MS11 2-742 
Hex/G+. N. gonorrhoeae 15253 and MS11 2-Hex/G+ both express lactose from HepI 743 
and HepII. Their mutants that lack HepII lactose were constructed by deleting lgtG 744 
(15253/G- and MS11 2-Hex/G-). 15253 Δlst lacks LOS sialyltransferase and cannot add 745 
Neu5Ac to LOS. MS11 4-Hex/G- expresses the sialylatable LNnT structure from HepI 746 
and served as a positive control for sialylation. All strains were in media with (+) or 747 
without (-) added CMP-Neu5Ac (100 µg/ml) for 2 h at 37 °C. Bacterial lysates were 748 
digested with protease K, separated on a 16% Tricine gel and LOS was visualized by 749 
silver staining. Retardation of LOS mobility following growth in CMP-Neu5Ac-containing 750 
media relative to LOS from bacteria grown in media devoid of CMP-Neu5Ac indicates 751 
sialylation.   752 
 753 
Fig. 3. Enhanced FH binding upon LOS sialylation is restricted to strains that express 754 
the LNnT LOS structure. FH binding to isogenic LOS mutants of MS11 that express 2-755 
Hex (lactose), 3-Hex (PK-like) or 4-Hex (LNnT) structures from HepI, with (G+) or 756 
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without (G-) lactose extensions from HepII were grown in media alone or media 757 
containing CMP-Neu5Ac (25 µg/ml). Bacteria were incubated with FH (10 µg/ml) and 758 
bound FH measured by flow cytometry. Black bars, unsialylated bacteria; grey bars, 759 
sialylated bacteria. Control reactions, where FH was excluded, showed a median 760 
fluorescence below 10. Y-axis, median fluorescence (mean [range] of 2 separate 761 
observations).  762 
 763 
Fig. 4. Sialylation of 15253 LOS inhibits complement activation. Strains 15253 and its 764 
isogenic mutant derivatives, 15253/G- (lacks HepII glycan extensions) and 15253 Δlst 765 
(lacks LOS sialyltransferase) were grown without or with CMP-Neu5Ac (25 µg/ml), 766 
incubated in 15% normal mouse serum for 20 min at 37 °C.  C3 deposited on the 767 
bacterial surface was measured by flow cytometry. C3 deposited on bacteria grown in 768 
the presence or absence of CMP-Neu5Ac is shown by the grey shaded and solid black 769 
line histograms, respectively. Controls (no serum added) are shown by the broken lines. 770 
Numbers alongside histograms represent median fluorescence intensity (the border or 771 
shading of the text boxes that contain the numbers) correspond to that of the 772 
histograms). X-axis, fluorescence (log10 scale); Y-axis, counts. One representative 773 
experiment of at least two reproducible repeats is shown.  774 
 775 
Fig. 5. Complement inhibition by MS11 mutants that express lactose LOS extensions. 776 
Isogenic MS11 mutants that express predominantly lactose (2-Hex), PK structure (3-777 
Hex) or LNnT (4-Hex) from HepI, with (G+) or without (G-) lactose from HepII, were 778 
grown in the absence or presence of CMP-Neu5Ac (25 µg/ml) and were incubated with 779 
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15% normal mouse serum for 20 min at 37 °C. Mouse C3 deposited on the bacterial 780 
surface was measured by flow cytometry. C3 deposited on bacteria grown in the 781 
presence or absence of CMP-Neu5Ac is shown by the grey shaded areas and solid 782 
black lines, respectively. Controls (no serum added) are shown by the broken lines. 783 
Numbers alongside histograms represent median fluorescence intensity (the border or 784 
shading of the text boxes that contain the numbers) correspond to that of the 785 
histograms). X-axis, fluorescence (log10 scale); Y-axis, counts. One representative 786 
experiment of at least two reproducible repeats is shown.  787 
 788 
 789 
Fig. 6. Neu5Ac added to HepII lactose resists removal by α2-3-sialidase.  MS11 2-Hex-790 
G+ and 15253 were grown in the absence or presence of CMP-Neu5Ac (25 µg/ml). 791 
MS11 4-Hex/G-, which expresses LNnT that is sialylated through an α2-3-linkage and 792 
MS11 3-Hex/G-, which expresses the PK-like LOS that becomes sialylated through an 793 
α2-6-linkage, were used as positive and negative controls for desialylation, respectively. 794 
Bacteria were treated with recombinant α2-3-specific sialidase or with neuraminidase 795 
(sialidase) buffer alone, then incubated with 15% normal mouse serum for 20 min at 37 796 
°C.  Mouse C3 deposited on bacteria (shown as median fluorescence intensity (MFI) on 797 
the Y-axis) was measured by flow cytometry. Controls (no added serum) showed 798 
fluorescence less than 10 units and have been omitted for simplicity. Each bar 799 
represents the mean (range) of two separate experiments.  800 
 801 
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Fig. 7. Sialyation of HepII lactose enhances virulence of strain 15253. Cmah knockout 802 
mice that express only Neu5Ac (the form of sialic acid found in humans), but not 803 
Neu5Gc (the form in wild-type mice), were infected with wild-type (WT) N. gonorrhoeae 804 
15253 (5.5 x 107 CFU) and its isogenic mutants 15253/G- (lacks any HepII glycan 805 
extension; 4.3 x 107 CFU) and 15253 Δlst (lacks LOS sialyltransferase; 4.9 x 107 CFU) 806 
(n=10 mice per group). Vaginas were swabbed daily to enumerate N. gonorrhoeae 807 
CFUs. A. Kaplan Meier curves showing time to clearance. WT bacteria versus G- and 808 
WT versus Δlst, P<0.0001 by Mantel-Cox log-rank test. B. CFU versus time. X-axis, 809 
day; Y-axis, CFU (log10). C. Area Under Curve (AUC) analysis for consolidated bacterial 810 
burden over time. Pairwise comparisons between G- and Δlst with the control group 811 
were made by Mann-Whitney’s non-parametric t test. Comparisons across groups were 812 
made by one-way ANOVA (Kruskal-Wallis non-parametric test; P<0.0001).  813 
 814 
Fig. 8. Effect of HepII lactose sialylation on the binding and bactericidal efficacy of mAb 815 
2C7. A. Sialylation decreases binding of mAb 2C7 to MS11 2-Hex/G+, but not to 15253. 816 
N. gonorrhoeae were grown in media alone or media supplemented with 25 µg/ml CMP-817 
Neu5Ac and binding of mAb 2C7 (10 µg/ml) to 15253 (left graph) and MS11 2-Hex/G+ 818 
was measured by flow cytometry. The solid black line shows mAb 2C7 binding to 819 
unsialylated bacteria; the grey shaded histogram, mAb 2C7 binding to sialylated 820 
bacteria. The control indicates bacteria incubated with anti-mouse IgG-FITC (no added 821 
mAb 2C7). One experiment of two reproducible repeats is shown. B. Addition of CMP-822 
Neu5Ac to growth media in increasing concentrations decreases the bactericidal 823 
efficacy of mAb 2C7 against N. gonorrhoeae 15253.  Serum bactericidal assays were 824 
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performed with 20% pooled normal human serum (NHS) as the complement source. 825 
Where indicated, mAb 2C7 was added to a concentration of 10 µg/ml. Y-axis, percent 826 
survival following incubation of the reaction for 30 min relative to survival at 0 min.  827 
 828 
Fig. 9. mAb 2C7 is attenuates infection with N. gonorrhoeae in the murine vaginal 829 
colonization model. Wild-type BALB/c mice were treated with either mAb 2C7 (10 µg 830 
intraperitoneally twice a day on days -2, -1 and 0) or a similar dose of control mouse 831 
IgG3 and then infected with 5 x 105 CFU of 15253. Vaginas were swabbed daily to 832 
enumerate CFUs. A. Kaplan Meier curves showing time to clearance. The two groups 833 
were compared using the Mantel-Cox log-rank test. B. CFU versus time. X-axis, day; Y-834 
axis, CFU (log10). C. Area Under Curve (AUC) analysis showing consolidated bacterial 835 
burdens over time. Pairwise comparisons between the two groups were made by Mann-836 
Whitney’s non-parametric t test.  837 
 838 
Fig. 10. Expression of the 2C7 LOS epitope by clinical isolates from Nanjing, China and 839 
bactericidal efficacy of mAb 2C7. A. Schematic showing reactivity of anti-LOS mAbs 840 
2C7, L1, L8 and 3F11. mAb 2C7 requires expression of lactose from HepI and HepII 841 
simultaneously (53). mAb L8 recognizes lactose from HepI in conjunction with a 842 
phosphoethanolamine (PEA) at the 3-position of HepII (74). Expression of 3-PEA from 843 
HepII requires lgtG to be phase-varied ‘OFF’, thus binding of mAb 2C7 and L8 occur 844 
exclusively and do not bind to overlapping epitopes. mAb 3F11 binds to unsialylated 845 
terminal lactosamine of the LNnT structure; any extension beyond lactosamine – for 846 
example with GalNAc [lgtD phase-varied ‘ON’] or the addition of Neu5Ac by adding 847 
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CMP-Neu5Ac to growth media – abrogates mAb 3F11 binding (73). mAb L1 binds to the 848 
PK-like globotriose structure (Galα(1,4)-Galβ(1,4)-Glc) (75). B. Reactivity of mAbs 2C7, 849 
L1, L8 and 3F11 to 75 minimally passaged N. gonorrhoeae isolates recovered from men 850 
with urethritis attending the Nanjing (China) STD clinic.  Binding of mAbs was 851 
determined by whole-cell ELISA. mAbs 2C7, L1 and L8 are all mouse IgG, while 3F11 is 852 
IgM, therefore shown as a separate graph. C. Complement-dependent bactericidal 853 
activity of mAb 2C7 against the first 62/75 isolates collected from men with urethritis in a 854 
Nanjing (China) study of gonococcal transmission from men to women as a function of 855 
mAb 2C7 binding.  Bacteria were grown in media containing CMP-Neu5Ac (2 µg/ml) to 856 
enable them to fully resist killing (>100% survival) by 16.7% normal human serum 857 
(NHS). Survival of bacteria at 30 min following incubation with mAb 2C7 (5 µg/ml) plus 858 
NHS (16.7%) is shown as a function of mAb 2C7 binding (X-axis).  859 
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